Peer-reviewed veterinary case report
Medroxyprogesterone acetate linked to higher risk of mammary tumors
By STØOVRING, MERETE et al.·Published in APMIS·1997·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A population‐based case‐control study of canine mammary tumours and clinical use of medroxyprogesterone acetate
- Species:
- dog
Plain-English summary
A study found that female dogs (bitches) who received injections of medroxyprogesterone acetate (MPA), a hormone used to prevent heat cycles, had a higher risk of developing mammary tumors. In the group of dogs with diagnosed mammary tumors, 39% had received MPA, compared to only 21% in the group without tumors. Most of the tumors in the treated dogs were found to be malignant. This suggests that using MPA to manage heat cycles may increase the risk of serious health issues like mammary tumors in female dogs.
People also search for: dog mammary tumors treatment · medroxyprogesterone acetate side effects · female dog heat cycle risks
Abstract
We investigated whether or not an association could be found between mammary tumours and prior clinical use of medroxyprogesterone acetate (MPA) in bitches. A population‐based retrospective agematched case‐control study was designed based on interviews with the owners of the bitches. The proportion of bitches with diagnosed mammary tumours (group MT+, n = 98) that had received progestin injections was compared with the proportion in a control group without mammary tumours (group MT‐, n=98). In the case group 39%, and in the control group 21% of the bitches had been treated with MPA. A significantly higher number of bitches with mammary tumours had been exposed to progestins, compared with the control group without mammary tumours (odds ratio = 2.32, Chisquare=7.01, p=0.008). Bitches treated clinically with low doses of MPA to avoid oestrus were at a greater risk of developing mammary tumours, the majority of which were histologically malignant (91%).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1699-0463.1997.tb05057.x